<< back
ReachX logo

COVID-19 - Biopharma’s agility put at test

Research

Publication Date: 25 Mar 2020 - By Scitaris G. By Scitaris G.
Actionable
Differentiated

Thematic Multi Asset Global Pharmaceuticals Biotechnology

Scitaris, a leading biotech and pharma consultancy, is providing a perspective on the biological characteristics of the virus, including:

- implications on its transmission and potential ends to the pandemic

- focusing the race of the biopharma industry to finding a cure

- considerations for investors in the space

Scitaris Covid -19

Source: Scitaris

Pages: 6

Released: 25 Mar 2020

Download Report

The Author

Scitaris G.

Healthcare, Pharmaceuticals, Biotechnology

Ask a question

 

Most read

At ReachX, we are accelerating the world's most ambitious projects and deals
Solutions
Transactions services
CFO services
Interim services
Subscription Financing BETA
Clients
Growth companies
Institutional investors
Professional service firms
The Platform
Our Vision
Our Team
Our Advisors
Insights
T&Cs
 Privacy Policy
Cookies Policy
Compliance
Press
Contact Us
ReachX Limited is authorised and regulated by the Financial Conduct Authority
(FCA number 811226)

Copyright (c) ReachX, 2021. All rights reserved. Reproduction in whole or in part without permission is prohibited
ReachX is registered with the ICO (Information Commissioner's Office) in the UK
ReachX Limited has appointed DataRep as its Data Protection Representative for the purposes of GDPR
Fifth Floor, 11 Leadenhall Street, EC3V 1LP London, UK (registered)
120 Regent Street, W1B 5FE London, UK (business)